Antibody Formulations and Methods of Making Same
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application 61/004,992, filed Nov 30, 2007. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,883,146 | Protein Formulations and Methods of Making Same In force · High confidence | AbbVie Biotechnology Ltd. | In force | High confidence | ||
| US 9,085,619 | Anti-Tnf Antibody Formulations In force · High confidence | AbbVie Biotechnology Ltd. | In force | High confidence | ||
| US 11,167,030 | Protein Formulations and Methods of Making Same In force · Medium confidence | AbbVie Biotechnology Ltd. | In force | Medium confidence | ||
| US 11,191,834 | Protein Formulations and Methods of Making Same In force · Medium confidence | AbbVie Biotechnology Ltd. | In force | Medium confidence | ||
| US 8,420,081 | Antibody Formulations and Methods of Making Same In force · High confidence | AbbVie Biotechnology Ltd. | In force | High confidence | ||
| US 8,821,865 | HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS In force · High confidence | AbbVie Biotechnology Ltd. | In force | High confidence | ||
| US 12,799,192 | Risankizumab Compositions In force · High confidence | AbbVie Inc. | In force | High confidence | ||
| US 12,502,420 | Clostridium botulinum Serotype A Neurotoxin (BoNT/A) Sequence Variants In force · High confidence | AbbVie Inc. | In force | High confidence | ||
| Application 13/794,881 | Ultrafiltration and Diafiltration Formulation Methods for Protein Processing Abandoned Abandoned Dec 21, 2015 | AbbVie, Inc. | Abandoned | Abandoned Dec 21, 2015 | ||
| Application 14/473,775 | HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY FORMULATIONS Abandoned Abandoned Dec 15, 2015 | AbbVie Biotechnology Ltd. | Abandoned | Abandoned Dec 15, 2015 | ||
| 22 more patents in this group · Pro | ||||||
10 of 32 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 32.
8 of these are in force and held by AbbVie Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.